Alopecia Universalis Successfully Treated With Tofacitinib

The document described a case where a 19-year-old female with alopecia universalis (AU), a severe form of alopecia areata (AA), was successfully treated with tofacitinib, a JAK1/3 inhibitor. After previous treatments failed, she began taking tofacitinib in December 2015 and experienced significant hair regrowth by August 2016 without adverse effects. Tofacitinib works by inhibiting the JAK-STAT pathway, which is involved in hair follicle destruction. Despite its promise, the drug's high cost and potential risks, such as increased malignancy and infection, make its off-label use controversial. The document emphasized the need for more controlled studies to assess the safety and long-term efficacy of JAK inhibitors for AA.